{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:03:13Z","timestamp":1789736593412,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Endoscopic mucosal healing serves as a critical predictor for achieving long-term remission in Crohn\u2019s disease treatment. Recent data indicate that the effectiveness of healing varies based on the location of gastrointestinal inflammation. Additionally, reports suggest that antitumor necrosis factor-\u03b1 (anti-TNF-\u03b1) agents exhibit reduced efficacy in treating small intestinal inflammation compared to colorectal inflammation. Conversely, limited research exists regarding the impact of the anti-IL12\/23 agent ustekinumab (UST) on small intestinal inflammation. This study aimed to compare the effects of anti-TNF-\u03b1 agents and UST on small intestinal inflammation using propensity score analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective observational study involved 70 patients with Crohn\u2019s disease who had inflammation in the small intestine and had initiated treatment with either anti-TNF agents or UST between March 2015 and August 2021. Endoscopic findings were evaluated before treatment commencement and at 1\u20132 years post-treatment initiation. The propensity score was employed to compare the efficacy of TNF agents and UST on small bowel inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ustekinumab exhibited greater improvement in the small intestinal endoscopy score than anti-TNF-\u03b1 antibodies according to the propensity score analysis (inverse probability weighting; P\u2005=\u2005.0448). However, no significant disparity was observed in the overall improvement of endoscopic scores between UST and anti-TNF-\u03b1 antibodies (P\u2005=\u2005.5938).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study suggests that UST might be more effective than anti-TNF-\u03b1 agents in treating small intestinal inflammation in Crohn\u2019s disease.<\/jats:p><\/jats:sec>","DOI":"10.1093\/crocol\/otae033","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:34:46Z","timestamp":1715700886000},"source":"Crossref","is-referenced-by-count":3,"title":["Comparing the Effects of Anti-TNF Agent and Ustekinumab on Small Bowel Inflammation in Crohn\u2019s Disease: Inverse Probability Weighting With Stabilized Weights of Propensity Scores"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-4690","authenticated-orcid":false,"given":"Yuki","family":"Hirata","sequence":"first","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Department of Medical Statistics, Research & Development Center, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishida","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Mizuta","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Numa","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kakimoto","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University Second Department of Internal Medicine, , Takatsuki City, Osaka 569-0801, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"3","key":"2024061111310238700_CIT0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2024061111310238700_CIT0002","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/MEG.0000000000000881","article-title":"Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"Niv","year":"2017","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"2","key":"2024061111310238700_CIT0003","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Fr\u00f8slie","year":"2007","journal-title":"Gastroenterology."},{"issue":"10","key":"2024061111310238700_CIT0004","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.cgh.2019.11.025","article-title":"Complete endoscopic healing associated with better outcomes than partial endoscopic healing in patients with Crohn\u2019s disease","volume":"18","author":"Yzet","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2024061111310238700_CIT0005","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology."},{"issue":"9","key":"2024061111310238700_CIT0006","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u2019s disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024061111310238700_CIT0007","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology."},{"issue":"eCollection 2020","key":"2024061111310238700_CIT0008","doi-asserted-by":"crossref","first-page":"1756284820976923","DOI":"10.1177\/1756284820976923","article-title":"Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn\u2019s disease","volume":"13","author":"Wu","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"7","key":"2024061111310238700_CIT0009","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.cgh.2019.08.024","article-title":"Small bowel healing detected by endoscopy in patients with Crohn\u2019s disease after treatment with antibodies against tumor necrosis factor","volume":"18","author":"Takenaka","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2024061111310238700_CIT0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00535-013-0829-7","article-title":"Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn\u2019s disease under scheduled maintenance treatment","volume":"49","author":"Imaeda","year":"2014","journal-title":"J Gastroenterol."},{"issue":"3","key":"2024061111310238700_CIT0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cgh.2014.09.031","article-title":"Factors associated with short- and long-term outcomes","volume":"13","author":"Reinisch","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024061111310238700_CIT0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024061111310238700_CIT0013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12876-022-02271-4","article-title":"Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn\u2019s disease","volume":"22","author":"Hirayama","year":"2022","journal-title":"BMC Gastroenterol."},{"issue":"8","key":"2024061111310238700_CIT0014","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.16551","article-title":"Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn\u2019s disease","volume":"54","author":"Takenaka","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024061111310238700_CIT0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00431-017-3076-8","article-title":"Pediatric Crohn disease is characterized by Th1 in the terminal ileum and Th1\/Th17 immune response in the colon","volume":"177","author":"Savi\u0107 Mlakar","year":"2018","journal-title":"Eur J Pediatr."},{"issue":"3","key":"2024061111310238700_CIT0016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/2050640617727180","article-title":"Toll-like receptors 2 and 4 modulate intestinal IL-10 differently in ileum and colon","volume":"6","author":"Latorre","year":"2018","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"2024061111310238700_CIT0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ibd\/izab123","article-title":"Serum analyte profiles associated with Crohn\u2019s disease and disease location","volume":"28","author":"Boucher","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024061111310238700_CIT0018","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/gutjnl-2014-307916","article-title":"Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum","volume":"65","author":"Mann","year":"2016","journal-title":"Gut."},{"issue":"1","key":"2024061111310238700_CIT0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/den.12313","article-title":"Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn\u2019s disease","volume":"27","author":"Beppu","year":"2015","journal-title":"Dig Endosc"},{"issue":"10342","key":"2024061111310238700_CIT0020","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet."},{"issue":"10","key":"2024061111310238700_CIT0021","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024061111310238700_CIT0022","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"issue":"4","key":"2024061111310238700_CIT0023","first-page":"825","article-title":"The effects of ustekinumab on small intestinal lesions and stenotic lesions","volume":"84","author":"Wada","year":"2022","journal-title":"Nagoya J Med Sci."},{"issue":"6","key":"2024061111310238700_CIT0024","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ibd\/izac167","article-title":"Comparative effectiveness of ustekinumab and anti-TNF agent as first-line biological therapy in luminal Crohn\u2019s disease: a retrospective study from 2 referral centers","volume":"29","author":"Rivi\u00e8re","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024061111310238700_CIT0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2024061111310238700_CIT0026","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ibd.21905","article-title":"Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases","volume":"18","author":"Verdier","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024061111310238700_CIT0027","doi-asserted-by":"crossref","first-page":"e54562","DOI":"10.1371\/journal.pone.0054562","article-title":"Distinct profiles of effector cytokines mark the different phases of Crohn\u2019s disease","volume":"8","author":"Zorzi","year":"2013","journal-title":"PLoS One."},{"issue":"3","key":"2024061111310238700_CIT0028","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.3462","article-title":"In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn\u2019s disease","volume":"20","author":"Atreya","year":"2014","journal-title":"Nat Med."},{"issue":"5","key":"2024061111310238700_CIT0029","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000445262","article-title":"Predicting therapeutic response by in vivo molecular imaging in inflammatory bowel diseases","volume":"34","author":"Atreya","year":"2016","journal-title":"Dig Dis."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae033\/57604575\/otae033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae033\/58196080\/otae033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae033\/58196080\/otae033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T21:50:29Z","timestamp":1731966629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae033\/7671505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae033","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2024,4,1]]},"article-number":"otae033"}}